Filing Flows

Filing Flows › Companies › Endovia Health Sciences › Cash flow

Endovia Health Sciences cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$1.1M in Q2 2026 · −$5.5M over twelve months

Operating cash flow−$1.1M
Free cash flow−$1.1M

Analysis

In Q2 2026, Endovia Health Sciences generated −$1.1M of operating cash flow. That is $541K less than in Q2 2025 (−$551K).

Over the twelve months to Jun 30, 2026, operating cash flow was −$5.5M; the largest uses were operating cash flow ($5.5M), net borrowing (+) / repaid (−) ($1.0M); besides operations, cash came from shares issued ($3.6M), other financing ($3.3M); the cash balance rose by $227K.

Operating cash flow was −$1.1M against net income of −$2.1M. The largest differences: stock-based pay +$1.1M, payables −$280K, prepaid and other assets +$80K.

Free cash flow

Endovia Health Sciences: free cash flow by quarterEndovia Health Sciences: free cash flow by quarter−$2.6MQ3 2024−$920KQ4 2024−$808KQ1 2025−$551KQ2 2025−$2.5MQ3 2025−$991KQ4 2025−$930KQ1 2026−$1.1MQ2 2026
Operating cash flow less capital spending.
Endovia Health Sciences: operating cash flow against capital spendingEndovia Health Sciences: operating cash flow against capital spendingOperating cash flowCapital spending−$2.6M$0Q3 2024−$920K$0Q4 2024−$808K$0Q1 2025−$551K$0Q2 2025−$2.5M$0Q3 2025−$991K$0Q4 2025−$930K$0Q1 2026−$1.1M$0Q2 2026
Latest (Q2 2026): Operating cash flow −$1.1M, Capital spending $0.

Capital allocation, year by year

Endovia Health Sciences: where the cash came from (up) and went (down), by fiscal yearEndovia Health Sciences: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedCapital spendingFY2021: Operating cash flow −$14.7MFY2021: Shares issued $19.6M$19.6MFY2021FY2022: Operating cash flow −$14.0MFY2022: Net borrowing $3.4MFY2022: Shares issued $11.4MFY2022: Capital spending −$103K$14.8MFY2022FY2023: Operating cash flow −$10.2MFY2023: Net borrowing $5.8MFY2023: Capital spending −$14K$5.8MFY2023FY2024: Operating cash flow −$7.3MFY2024: Net borrowing $7.5MFY2024: Capital spending −$3K$7.5MFY2024FY2025: Operating cash flow −$4.8MFY2025: Net borrowing $3.6MFY2025: Shares issued $1.3M$4.9MFY2025
Over these 5 years operating cash flow totalled −$51.1M; the largest uses were operating cash flow ($51.1M) and capital spending ($120K). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$243K
Debt$1K
Net cash$242K
Cash runway1 month

Endovia Health Sciences is burning cash: its operations consume cash, a free cash flow of −$5.5M a year at the current rate against $243K of cash and investments: a runway of about 1 month before any new financing.

Where the cash came from and went

Endovia Health Sciences: sources (+) and uses (−) of cash, Q2 2026Endovia Health Sciences: sources (+) and uses (−) of cash, Q2 2026Shares issued$1.6MOperating cash flow−$1.1MOther financing−$1.0MNet borrowing (+) / repaid (−)$578KNot reconciled−$205KCash drawn (+) / kept (−)$138KExchange rates$2K
Endovia Health Sciences: sources (+) and uses (−) of cash, TTM to Q2 2026Endovia Health Sciences: sources (+) and uses (−) of cash, TTM to Q2 2026Operating cash flow−$5.5MShares issued$3.6MOther financing$3.3MNet borrowing (+) / repaid (−)−$1.0MCash drawn (+) / kept (−)−$227KNot reconciled−$128KExchange rates−$23K

From profit to cash

Endovia Health Sciences: net income to operating cash flow, Q2 2026Endovia Health Sciences: net income to operating cash flow, Q2 2026Net income−$6.6MDepreciation & amortization$8KStock-based pay$1.1MReceivables$6KPayables−$280KPrepaid and other assets$80KOperating cash flow−$1.1M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q1 2025239113952-599
Q3 202459176699-464

Every quarter

QuarterOperating cash flowNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$1.1M$578K$1.6M$138K−$1.1M
Q1 2026−$930K−$318K$1.4M−$100K−$930K
Q4 2025−$991K$330K$500K−$17K−$991K
Q3 2025−$2.5M$2.5M$149K−$248K−$2.5M
Q2 2025−$551K$45K—−$17K−$551K
Q1 2025−$808K$774K—$15K−$808K
Q4 2024−$920K$1.2M—$230K−$920K
Q3 2024−$2.6M$3.0M—−$449K−$2.6M

Endovia Health Sciences: income statement and cash flow

Endovia Health Sciences, Q1 2026: revenue $4K (-94% year over year). The chart follows the revenue to costs, profit and cash.

Endovia Health Sciences: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.